Tagged with

Australian Self Medication Industry(ASMI) Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements? The company was founded over a century ago by Leone Molteni in the backyard of Farmacia Molteni located in the…

Medicines Australia To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization comprises all major innovator companies, consisting of the significant American and European pharmaceutical players, in addition to some Australian companies…

SERVIER Laboratories (Australia) Pty Ltd Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why Servier has invested more in Australia of late. What drives Servier’s headquarters to conduct more research in Australia is a…

Solvay Australia How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1 price cut at this stage. Nevertheless, there are two other drugs fully affected by the cut (-25%). This of course…

Stiefel Laboratories Pty Limited What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company from having products on it in the future, there is no immediate effect or detriment to Stiefel due to the…

Bayer Australia Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines in the industry. In Australia, the company is launching in the next three years, 18 new products or product line…

Pharmaceutical Benefits Advisory Committee To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the Ministry of Health and Ageing as to what drugs will be listed on the Pharmaceutical Benefits Scheme (PBS). The Minister…

Argentina SA Baxter Do you think this is a good moment for the Argentinean pharmaceutical industry to have international exposure? Indeed it is attractive, but we should keep the long term objectives on perspective. It is a stable and interesting market for multinational companies, as long as they can grasp the dynamics of…

Bayer Thailand Mr. Ammelburg of Roche described Thailand as a very difficult and different market and according to PReMA figures there was only 2 percent growth last year. Nevertheless, global projections rank Thailand as 12th among emerging countries in pharma and anticipate Thailand becoming the eighth largest economy and market by 2016.…

Laboratorios Richmond What have been the recent major milestones for Richmond? One of the milestones for Laboratorios Richmond was to have developed the first branded oncological generic in the world. For Laboratorios Richmond to be developing combinations of different molecules from different originator laboratories is very important as well, as it provides…

Biogen Idec Argentina Biogen Idec’s arrival in Argentina has been very recent. Could you explain to our readers why the time was right to take back your licences and to set up in Argentina? Biogen Idec has a worldwide expansion strategy. Two years ago, the company decided to establish its own affiliates in…

CETIFARMA The Mexican government has been fairly pro-active about promoting good practice such as the new drug registration process that helped eliminate drugs from the Mexican market that didn’t fulfill regulatory therapeutic efficiency. In this context, what is left to do for CETIFARMA? In my opinion when the authorities take a…